Richard W. Pascoe

Mr. Pascoe was appointed CEO in January 2023 and has served as a director of Zevra Therapeutics (then KemPharm, Inc.) since January 2014 and as Zevra’s executive chairman since November 2021. In January 2023, Mr. Pascoe was appointed chief executive officer and remains a member of the board of directors. He served as lead independent director of Zevra from November 2014 to November 2021.

Mr. Pascoe served as president and chief executive officer of Histogen Inc, a biologics company, from January 2019 to November 2021. From March 2013 to January 2019, Mr. Pascoe was chief executive officer and a director of Apricus Biosciences, Inc., a specialty pharmaceutical company.

From August 2008 to March 2013, Mr. Pascoe was president and chief executive officer and a director of Pernix Sleep, Inc. (formerly known as Somaxon Pharmaceuticals, Inc.), a specialty pharmaceutical company.

Prior to Pernix, from 2005 to 2008, Mr. Pascoe worked for ARIAD Pharmaceuticals, Inc., a specialty pharmaceutical company, where he was most recently senior vice president and chief operating officer. Mr. Pascoe also serves as a director of Seelos Therapeutics, Inc., a specialty pharmaceutical company.

Mr. Pascoe received his Bachelor of Science from the United States Military Academy at West Point, and served as a captain in the U.S. Army.